Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Immune Design CS (NASDAQ: IMDZ)

$6.15 USD -$0.10 (-1.60%)
Last Price $6.15
Net Change $-0.1 (-1.6%)
Bid $0
Ask Price $0
Open Price $6.25
Previous Close Price $6.25
High Price $6.25
Low Price $5.95
Number of Trades 262
Volume 51,400
Fifty Two Week High $16.94 (2016-04-25)
Fifty Two Week Low $4.5 (2016-11-03)
Average Daily Volume 85,154
Share Outstanding 25,440 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $3.24
Recent Earnings $
Annual EPS $-2.49
Last Quarter EPS $
Market Capitalization $0.16B
Insider Shareholders % 0.429%
Annual Revenue $0B
No. Shares Outstanding 25,440
Inst. Shareholder % 51.7%
Annual Net Income $0B
TTM Net Profit Margin $100.53
1-Year Return -63.06%
3-Year Return -48.96%
5-Year Return -48.96%
5-Year Revenue Growth 0%
5-Year Earnings Growth 0%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD 3.24%
Dividends per Share $
Stock Split Ratio
Beta 2.72
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.

IMDZ News & Stock Updates